MedTrace Logo

Effects of High Ventilation Breathwork With Retention (HVBR) on Health

NCT06064474 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-12-20

No results posted yet for this study

Summary

The investigators are conducting a randomised-controlled trial comparing high ventilation breathwork with retention (HVBR) to a breathwork placebo (paced breathing at 15breaths/min with brief retentions). The metric of 15b/min aligns with guidance from the British Journal of Nursing, Royal College of Physicians and Johns Hopkins Medicine which state that the average, healthy rate should range from: 12-20, 12-18 and 12-16b/min, respectively. The main questions the study attempts to address are: Does HVBR lead to improved state and trait mental health and wellbeing in a general population adult sample?

The study will be conducted entirely online through the research platform Prolific, so participant data will be anonymous. The investigators will collect self-reports of mental health and wellbeing before and after the three-week breathwork period, in addition to a follow-up three weeks later. Pre-post intervention and follow-up questionnaires will be completed online via the survey platform Qualtrics which will be linked to Prolific. Data on self-reported adherence to, and credibility/expectancy of, the breathwork will also be collected, along with participants' experiences to gauge the safety and tolerability of the breathwork protocol.

Conditions

  • Stress
  • Anxiety
  • Depressive Symptoms
  • Mental Wellbeing
  • Positive Affect
  • Negative Affect
  • Sleep-Related Impairment

Interventions

BEHAVIORAL

High ventilation breathwork with retention (HVBR)

Intervention

BEHAVIORAL

Placebo HVBR

Placebo

Sponsors & Collaborators

Principal Investigators

  • Guy W Fincham, MSc · University of Sussex

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-13
Primary Completion
2023-12-11
Completion
2023-12-11

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06064474 on ClinicalTrials.gov